Crystal structures of active SRC kinase domain complexes.

c-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs. Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form. Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms. Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolutions ranging from 2.9A to 1.95A. The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation. The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340. In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.

[1]  N. Rosen,et al.  Activation of pp60c-src protein kinase activity in human colon carcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  John Kuriyan,et al.  Intramolecular Regulatory Interactions in the Src Family Kinase Hck Probed by Mutagenesis of a Conserved Tryptophan Residue* , 1998, The Journal of Biological Chemistry.

[3]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[4]  Satoru Takeuchi,et al.  Structure of the Carboxyl-terminal Src Kinase, Csk* , 2002, The Journal of Biological Chemistry.

[5]  J Mottram,et al.  Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. , 2000, Chemistry & biology.

[6]  Laurent Meijer,et al.  Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. , 2002, Biochemical pharmacology.

[7]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[8]  S. Hubbard,et al.  Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.

[9]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[10]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[11]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[12]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[13]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[14]  J. Kuriyan,et al.  Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.

[15]  S. Taylor,et al.  Domain movements in protein kinases. , 1994, Current opinion in structural biology.

[16]  R. Engh,et al.  The protein kinase activity modulation sites: mechanisms for cellular regulation - targets for therapeutic intervention. , 2001, Advances in enzyme regulation.

[17]  S. Harrison,et al.  Variation on an Src-like Theme , 2003, Cell.

[18]  L. Toledo,et al.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.

[19]  A. P. Czernilofsky,et al.  Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product , 1980, Nature.

[20]  Michael J. Eck,et al.  Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.

[21]  G. Superti-Furga,et al.  The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. , 1997, Journal of molecular biology.

[22]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[23]  D. Fabbro,et al.  The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. , 2005, Structure.

[24]  T. Yamamoto,et al.  CSK: a protein-tyrosine kinase involved in regulation of src family kinases. , 1991, The Journal of biological chemistry.

[25]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[26]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[27]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[28]  T. Boggon,et al.  Structure and regulation of Src family kinases , 2004, Oncogene.

[29]  S. K. Shore,et al.  SRC in human carcinogenesis. , 2003, Frontiers in bioscience : a journal and virtual library.

[30]  Giulio Superti-Furga,et al.  Dynamic Coupling between the SH2 and SH3 Domains of c-Src and Hck Underlies Their Inactivation by C-Terminal Tyrosine Phosphorylation , 2001, Cell.

[31]  M. Šuša,et al.  A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. , 1999, Bone.

[32]  John Kuriyan,et al.  Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.

[33]  S. Hubbard.  Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[34]  J. Pipas,et al.  pp60c-src activation in human colon carcinoma. , 1989, The Journal of clinical investigation.

[35]  E. Altmann,et al.  Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. , 2000, Bioorganic & medicinal chemistry letters.

[36]  M. Lamers,et al.  Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. , 1999, Journal of molecular biology.

[37]  Duncan E McRee,et al.  Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. , 2002, Structure.

[38]  G. Superti-Furga,et al.  Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis , 1999, Nature Structural Biology.

[39]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[40]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[41]  S. Harrison,et al.  Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.

[42]  M. Frame,et al.  Src in cancer: deregulation and consequences for cell behaviour. , 2002, Biochimica et biophysica acta.

[43]  L. Johnson,et al.  Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity* , 1999, The Journal of Biological Chemistry.

[44]  Anthony C. Bishop,et al.  Structural basis for selective inhibition of Src family kinases by PP1. , 1999, Chemistry & biology.

[45]  T. Hunter,et al.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine , 1980, Proceedings of the National Academy of Sciences.

[46]  J. Mester,et al.  Cellular effects of purvalanol A: A specific inhibitor of cyclin‐dependent kinase activities , 2002, International journal of cancer.

[47]  W. Gilbert,et al.  Nucleotide sequence of rous sarcoma virus , 1983, Cell.